| AstraZeneca: Court denies Teva motion on Pulmicort Respules | Posted on 26/09/2008 in Pharmaceutical Company Product News AstraZeneca has announced that a court has denied the motion from Teva for summary judgement in the patent litigation for Pulmicort Respules (budesonide inhalation suspension).
Teva has called for a judgement of no infringement in this case, but this was denied by the US District Court for the District of New Jersey.
Furthermore, the court said a trial date will be scheduled shortly and is likely to occur in January 2009.
AstraZeneca said it has remained focused on its preparation for this trial and expressed confidence in the robustness of its intellectual property protecting this compound.
"In October of 2005, AstraZeneca announced that it had filed a lawsuit in the US District Court for the District of New Jersey against Ivax Pharmaceuticals - now known as Teva Pharmaceutical Industries - for patent infringement," the company added.
It noted this lawsuit followed a new drug application to market a generic form of Pulmicort Respules before its patent expired in 2018.
AstraZeneca also said the US Food and Drug Administration has not approved a generic formulation of the compound and has not yet responded to the company's citizen petition filed in 2006.
Earlier this week, AstraZeneca and Targacept announced inconclusive top-line results from their phase IIb study of AZD3480 in patients with Alzheimer's disease.Other news stories from 26/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
